Women living with HER2 positive breast cancer now have a new treatment option for the first time in almost ten years. Health Canada has approved TykerbTM (lapatinib ditosylate) tablets for use in combination with an oral chemotherapy, capecitabine (Xeloda®), for the treatment of patients with advanced or metastatic breast cancer whose tumours overexpress HER2 (ErbB2) and who have progressed following prior therapies including taxanes, anthracyclines and trastuzumab (Herceptin®).
More...